Our customers say

Xplico Evaluator is an integrated part of our financial models and is used for valuation of single projects, deal making as well as valuation of the whole company. It is a sophisticated tool for the experienced user, yet easy to navigate in and transparent – no black box, which is good! Use Xplico for technical questions as well as a sparring partner, they give fast and valid feedback and there are many years of real-world experience to learn from.
Helle Størum, Business Development Manager, Zealand Pharma
The Xplico software has been an invaluable tool to help Embera, a development stage specialty pharma company, develop and maintain models for the various indications of EMB-001. The Xplico software provides and clear concise methodology to understand and value the market opportunities and the capital required to realize those opportunities based a set of assumptions that can be easily modified as assumptions change over time. The Xplico organization also provides great support for their product to ensure that we are utilizing the full capabilities for the software including their own deep experience modeling pharma/biotech product opportunties.
Bob Linke, Embera NeuroTherapeutics, Inc.
Bavarian Nordic is using Xplico Evaluator to prepare licensing negotiations with potential partners. It’s really important to have a process that facilitates communication around the forecast, be it the assumptions, the results, caveats and the deal valuation. Having a solid and consistent process helps to lend a sense of confidence to the team who is discussing deal valuation with our partners. In addition we enjoyed Xplico expert support. Xplico quickly validated our efforts and supported us with hands on training when needed.
Jürgen Langhärig, Ph.D; M.B.A., VP Business Development, Bavarian Nordic
We have found the Xplico platform to be a very capable and cost-effective solution for analyzing both internal and external licensing and product development opportunities.
H Casey Logan, Chief Business Officer, TRACON Pharmaceuticals, Inc
Oxford Biomedica has adopted Xplico Evaluator as a tool to evaluate internal and external assets. Xplico proved to be a flexible, robust valuation model with extensive analysis features and easy reporting module. I would highly recommend it even to those with extensive experience in valuations. It saves time and allows one to concentrate on other aspects of striking a deal.
Spiros Servos Ph.D, MBA,Director, Business Development, Oxford BioMedica (UK) Ltd
…in addition to the user-friendly Xplico Valuation-tool I have also been most satisfied with the easy access to individual ‘user-service’ provided by the Xplico consultants to enable me to quickly get the model up-and-running as well as to solve any potential difficulties or challenges underway while using the tool — highly recommendable!….
Morten Faester, Director Business Development, Medivir AB
Xplico has been instrumental in our recent licensing negotiations. It is easy to work with and the only tool I am aware of that integrates both the financial and commercial requirements of modeling the deal-making process specifically in pharma and biotech!
Heiner Pieper,Vice President BD & Licensing, PharmaMar SA
I have been using Xplico for over one year now and it has proven to be a very useful tool for designing transactions and product valuations. The support of Xplico is fast and to the point. All in all, a great tool!
Hans Preusting, CBO, uniQure
4SC is using Xplico Evaluator to analyse and valuate internal and external assets and product opportunities. The Xplico tool has proven to be well-structured and flexible with powerful analysis features and very useful outputs for presentation purposes. The tool is backed up by quick and valid support from Xplico. I can definitely recommend the tool to other biotech companies.
Dr. Manfred Groeppel, Director Business Development, 4SC AG